Argus upgraded Hologic (HOLX) to Buy from Hold with an $80 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic management to meet virtually with BTIG
- Hologic’s Growth Prospects and Valuation Underscore Buy Rating
- Hologic upgraded to Outperform from Sector Perform at RBC Capital
- Hologic price target raised to $69 from $65 at Morgan Stanley
- Hologic’s Hold Rating: Balancing Molecular Diagnostics Growth with Breast Health Challenges and External Headwinds